Mara's email arrived in November of 2015 with an attachment and almost no explanation, a one-line note saying the enclosed reflected current performance metrics as requested. I'd been requesting metrics since March, through three unanswered calls and two investor newsletters that talked about momentum and partnerships but never once about accuracy rates.
The spreadsheet had five columns. Two of them were blank except for the word pending, repeated down the page like a chant. The columns that did have numbers covered device counts and retail locations signed, not the thing Amos and I actually needed to know, which was whether the tests coming out the far side of that steel door were right.
I printed it and drove to the quarterly investor meeting later that November with it folded in my coat pocket, the same pocket location, I noticed uncomfortably, where Amos still carried my handwritten note. I wanted an answer before another newsletter could turn the empty columns into something that sounded like progress.
Gideon ran the meeting from the front of a conference room full of people nodding at slides about expansion into new states and a growing device fleet. When the floor opened for questions, I stood up before I'd fully decided to.
"Your own numbers here show two major accuracy categories still listed as pending," I said, holding up the sheet. "Your slides just told us we're in forty retail locations. I'd like to understand how you're in forty locations without those two columns filled in."
The room went the particular kind of quiet that happens when a question is honest and everyone else in the room had decided not to ask it.
"We're scaling validation alongside deployment," Gideon said. "That's standard in this industry. We'll have full category data as we move through the coming year, and frankly, the market opportunity doesn't wait for every column to close before we capture it."
"That's a plan for next year," I said. "I'm asking about what's running in retail locations right now, today, with customers' actual blood."
He didn't answer that question so much as he answered an adjacent one, about milestones reached, about a pharmacy chain renewing its agreement, about the device fleet doubling by summer. It was a fluent answer and it left my question sitting exactly where I'd put it, unaddressed.
Afterward Mara caught me in the hallway, her voice lower than it had been in the room. "The categories aren't fabricated," she said. "They're incomplete. There's a difference."
"Not to the people whose blood is in forty retail locations," I said, and she didn't have an answer for that one either, just a tightening around her mouth that told me she'd had this argument with someone before, maybe with Gideon, maybe only with herself.
I told my account representative that week I wouldn't be increasing my position in the spring round, and I meant it as the line I wouldn't cross, the one firm boundary I could hold even if I couldn't undo what I'd already put in.
When Amos asked that weekend how the meeting went, I told him expansion was running a little behind schedule, nothing alarming, startups always hit friction scaling up. I did not show him the spreadsheet. I did not mention the word pending, repeated twice down a page I still had folded in my coat.
He nodded like a man who'd heard a hundred reasonable-sounding delays across forty years of equipment deals, and went back to describing the house near their daughter that he and Darlene were now planning to buy once the next funding round paid out. I let him keep describing it. I told myself I was protecting him from worry over something that might still resolve itself, and some smaller, quieter part of me understood that I was protecting the version of myself that he still believed had watched that machine run clean from start to finish.